CARTESIAN THERAPEUTICS INC (RNAC) Stock Price, Quote, News and Overview
NASDAQ:RNAC - Nasdaq - US8162123025 - Common Stock - Currency: USD
RNAC Quote, Performance and Key Statistics
10.68
-0.78 (-6.81%)
The current stock price of RNAC is 10.68 USD. In the past month the price increased by 6.8%. In the past year, price decreased by -60.46%.
RNAC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.75 | 322.03B | ||
| AMGN | AMGEN INC | 13.35 | 149.02B | ||
| GILD | GILEAD SCIENCES INC | 14.3 | 137.67B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.76 | 56.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.09B | ||
| ARGX | ARGENX SE - ADR | 97.42 | 34.20B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 26.09B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.65B | ||
| NTRA | NATERA INC | N/A | 22.93B | ||
| BIIB | BIOGEN INC | 7.97 | 18.47B | ||
| INSM | INSMED INC | N/A | 18.12B |
Related stock screener links
About RNAC
Company Profile
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Frederick, Maryland and currently employs 66 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Company Info
CARTESIAN THERAPEUTICS INC
7495 New Horizon Way
Frederick MARYLAND US
Employees: 66
Phone: 13013488698
CARTESIAN THERAPEUTICS INC / RNAC FAQ
What is the stock price of CARTESIAN THERAPEUTICS INC today?
The current stock price of RNAC is 10.68 USD. The price decreased by -6.81% in the last trading session.
What is the ticker symbol for CARTESIAN THERAPEUTICS INC stock?
The exchange symbol of CARTESIAN THERAPEUTICS INC is RNAC and it is listed on the Nasdaq exchange.
On which exchange is RNAC stock listed?
RNAC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CARTESIAN THERAPEUTICS INC stock?
14 analysts have analysed RNAC and the average price target is 36.89 USD. This implies a price increase of 245.41% is expected in the next year compared to the current price of 10.68. Check the CARTESIAN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CARTESIAN THERAPEUTICS INC worth?
CARTESIAN THERAPEUTICS INC (RNAC) has a market capitalization of 277.15M USD. This makes RNAC a Micro Cap stock.
How many employees does CARTESIAN THERAPEUTICS INC have?
CARTESIAN THERAPEUTICS INC (RNAC) currently has 66 employees.
What are the support and resistance levels for CARTESIAN THERAPEUTICS INC (RNAC) stock?
CARTESIAN THERAPEUTICS INC (RNAC) has a support level at 10.5 and a resistance level at 11.04. Check the full technical report for a detailed analysis of RNAC support and resistance levels.
Is CARTESIAN THERAPEUTICS INC (RNAC) expected to grow?
The Revenue of CARTESIAN THERAPEUTICS INC (RNAC) is expected to decline by -91.26% in the next year. Check the estimates tab for more information on the RNAC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CARTESIAN THERAPEUTICS INC (RNAC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RNAC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RNAC, evaluating the profitability, health, valuation and growth aspects
- CARTESIAN THERAPEUTICS INC (RNAC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CARTESIAN THERAPEUTICS INC (RNAC) Sales and EPS estimates to see what analysts future expectations are.
- CARTESIAN THERAPEUTICS INC (RNAC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CARTESIAN THERAPEUTICS INC (RNAC) Insider and Institutional Ownership to learn about the owners and their transactions.
- CARTESIAN THERAPEUTICS INC (RNAC) Stock Chart to make your own analysis
- CARTESIAN THERAPEUTICS INC (RNAC) Latest news and press-releases to stay up to date.
Does CARTESIAN THERAPEUTICS INC (RNAC) stock pay dividends?
RNAC does not pay a dividend.
When does CARTESIAN THERAPEUTICS INC (RNAC) report earnings?
CARTESIAN THERAPEUTICS INC (RNAC) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of CARTESIAN THERAPEUTICS INC (RNAC)?
CARTESIAN THERAPEUTICS INC (RNAC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.86).
What is the Short Interest ratio of CARTESIAN THERAPEUTICS INC (RNAC) stock?
The outstanding short interest for CARTESIAN THERAPEUTICS INC (RNAC) is 43.99% of its float. Check the ownership tab for more information on the RNAC short interest.
RNAC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RNAC. When comparing the yearly performance of all stocks, RNAC is a bad performer in the overall market: 95.16% of all stocks are doing better.
RNAC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RNAC. RNAC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RNAC Financial Highlights
Over the last trailing twelve months RNAC reported a non-GAAP Earnings per Share(EPS) of -1.86. The EPS increased by 88.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.39% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RNAC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to RNAC. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 71.04% and a revenue growth -91.26% for RNAC